Search Results

News | 24 March 2018
...million to improve the treatment services and market for paediatric TB medicines and incorporate TB control into HIV, maternal and child health services in India and nine African countries. US...

News | 15 July 2021
...and Bionote and Mologic to transfer know-how to DIATROPIX of the Institut Pasteur de Dakar (Senegal) Separate partnership between Viatris (South Africa) and Guangzhou Wondfo Biotech (China) supported to enable...

News | 12 December 2014
...three years. Furthermore, it will generate 40% cost savings for the testing procedure overall. ‘Bringing testing closer to infants is vital,’ said Lelio Marmora, Executive Director of UNITAID. ‘With poor...

News | 26 July 2021
...and middle-income countries. We look forward to seeing policymakers across the globe move expeditiously forward to accelerate access to this very important drug for communities.” Second- and third-line therapies are...

News | 25 January 2023
...rates of effectiveness Interceptor® G2 bed nets use a new insecticide for combatting mosquitoes, providing an urgently needed alternative to kick-start plateauing progress against malaria More than 60 million people...

News | 04 October 2021
...treatment and have the best possible health outcomes.” The investments from Unitaid will accelerate both companies’ paediatric delivery mechanisms, covering pre-clinical work for several different potential applications. Professor John Reeder...

News | 04 October 2021
...implemented in 13 high volume sites, and is expected to generate early experience, enabling younger children <20kgs access to the clinically superior benefits of DTG. Lessons learnt during first phase...

News | 23 February 2022
...liquid oxygen, oxygen plant repairs, and critical parts (e.g., zeolite, compressors, etc.) Strengthen advocacy and communication efforts to highlight the importance of oxygen and accelerate financing available via the ACT-A...

News | 13 November 2018
...affordable prices. The deal will allow manufacturers in 99 countries to develop and sell generic versions containing glecaprevir/pibrentasvir (G/P). This oral, eight-week regimen has cure rates of 98 percent across...

News | 04 September 2017
...epidemic. Scaling up new, safer, shorter regimens for the programmatic management of latent TB infection has the potential to accelerate progress to ending the TB epidemic,” said Professor Gavin Churchyard,...